Nicole Cincinnati
Family · Wyomissing, PANPI 1952367237
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $7,938 of the $10,210 with a category attached, or 77.7%. It is spread thinly across 39 manufacturers, the largest accounting for just 21.9% — the pattern of someone who eats at a lot of different presentations. 2025 is the largest year on record at $2,814, 2.4 times the $1,165 reported in 2021. Among family clinicians in PA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 356 payments — averaging $28.68 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Senseonics, Incorporated$2K
- AstraZeneca$1K
- AbbVie$813
- Boehringer Ingelheim$668
- Bayer$538
- Novo Nordisk$399
- plus $4K from 33 others
What the payments were for
- Consulting fees$4004%
- Speaking & faculty fees$1,84018%
- Food & beverage$7,93878%
- Education$320%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Senseonics, Incorporated | 6 | $2,240 |
| AstraZeneca(2 entities) | 39 | $1,124 |
| AbbVie | 37 | $813 |
| Boehringer Ingelheim | 27 | $668 |
| Bayer | 27 | $538 |
| Novo Nordisk | 21 | $399 |
| Vifor Pharma, Inc. | 17 | $388 |
| Calliditas Therapeutics US Inc. | 14 | $372 |
| Fresenius USA Marketing, Inc. | 18 | $365 |
| Lilly USA, LLC | 12 | $235 |
| Ardelyx, Inc. | 7 | $233 |
| Daiichi Sankyo Inc. | 10 | $199 |
| Otsuka America Pharmaceutical, Inc. | 7 | $193 |
| Travere Therapeutics, Inc. | 11 | $191 |
| Amarin Pharma, Inc. | 16 | $177 |
| GSK | 5 | $175 |
| Medtronic | 8 | $171 |
| Amgen(2 entities) | 7 | $166 |
| Xeris Pharmaceuticals, Inc. | 7 | $156 |
| Mallinckrodt Hospital Products Inc. | 5 | $141 |
| Dexcom, Inc. | 6 | $133 |
| Scpharmaceuticals Inc. | 2 | $128 |
| Corcept Therapeutics | 7 | $128 |
| Mannkind Corporation | 3 | $113 |
| Tandem Diabetes Care, Inc. | 6 | $109 |
| Sanofi-aventis U.S. LLC | 5 | $105 |
| Merck | 5 | $92 |
| Takeda Pharmaceuticals U.S.A., Inc. | 3 | $79 |
| Abbott | 3 | $65 |
| Shield Therapeutics Inc | 1 | $52 |
| BD | 2 | $51 |
| Aurinia Pharma U.S., Inc. | 2 | $46 |
| Ascensia Diabetes Care US Inc. | 2 | $39 |
| Kowa Pharmaceuticals America, Inc. | 2 | $27 |
| Esperion Therapeutics, Inc. | 2 | $26 |
| BETA Bionics, Inc. | 1 | $21 |
| Insulet Corporation | 1 | $19 |
| Chiesi USA, Inc. | 1 | $18 |
| Biomerieux Inc | 1 | $17 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$10,210 in reported general payments places this provider in the 95th percentile of 4,717 family providers in Pennsylvania.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| VelphoroSucroferric Oxyhydroxide | 34 | $139,934 |
| Tolvaptan | 11 | $76,220 |
| FarxigaDapagliflozin Propanediol | 73 | $63,546 |
| VeltassaPatiromer Calcium Sorbitex | 54 | $44,188 |
| LokelmaSodium Zirconium Cyclosilicate | 34 | $25,094 |
| KerendiaFinerenone | 15 | $14,154 |
| JardianceEmpagliflozin | 19 | $12,928 |
| Sevelamer Carbonate | 95 | $12,693 |
| TradjentaLinagliptin | 11 | $9,855 |
| Cinacalcet Hcl | 16 | $9,096 |
| Calcium Acetate | 104 | $7,291 |
| Lanthanum Carbonate | 12 | $6,955 |
| Calcitriol | 103 | $1,993 |
| Potassium Citrate ErPotassium Citrate | 13 | $1,827 |
| Bumetanide | 36 | $1,774 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Fresenius USA Marketing, Inc.Velphoro | $365 | $139,93434 claims |
| AstraZenecaFarxiga, Lokelma | $1,124 | $88,640107 claims |
| Boehringer IngelheimJardiance, Tradjenta | $668 | $22,78330 claims |
| BayerKerendia | $538 | $14,15415 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 4,717 family providers in Pennsylvania.
Other family in Wyomissing
- Kathleen ScholzPittsburgh$397K
- Shannon FitzgeraldAllison Park$370K
- Stephanie HarshbargerCamp Hill$317K
- Whitney BowlesFort Washington$253K
- Kweilynn GreenePittsburgh$139K
- Kami NestlerWilkes Barre$129K
- Bethany ThomasPhiladelphia$126K
- Margaret RosenzweigPittsburgh$89K
- Amanda GrippoDickson Cty$86K
- Patricia HabdasPittsburgh$83K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.